Patent · US Active

Anti-CD40 antibodies and uses thereof

US11976123B2 · kind B2 · utility

0Cited by

2References

17Claims

0Family size

Assignee

LYVGEN BIOPHARMA HOLDINGS LIMITED · CN

Inventors

Jieyi Wang · Lake Bluff, US
Yi-Ting Wu · Shanghai, CN

Key dates

Filing date	Apr 19, 2019
Grant date	May 7, 2024
Priority date	—
Expiry date	Jul 8, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Disclosed herein are agnostic anti-CD40 antibodies and methods of using such for eliciting CD40 signaling, thereby enhancing immune responses, such as dendritic cell functions. The antibodies disclosed herein may be used to treat diseases, such as cancer and immune disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.